Souders Financial Advisors Allogene Therapeutics, Inc. Transaction History

Souders Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$13.13 - $24.52 $312,323 - $583,257	-23,787 Closed	0 $0
Q3 2021 Nov 03, 2021	BUY	$21.01 - $27.64 $26,661 - $35,075	1,269 Added 5.64%	23,787 $611,000
Q2 2021 Aug 09, 2021	BUY	$23.49 - $35.8 $101,241 - $154,298	4,310 Added 23.67%	22,518 $587,000
Q1 2021 May 13, 2021	BUY	$25.79 - $39.02 $59,291 - $89,706	2,299 Added 14.45%	18,208 $643,000
Q4 2020 Feb 09, 2021	BUY	$25.24 - $43.45 $34,376 - $59,178	1,362 Added 9.36%	15,909 $402,000

Q3 2020 Nov 12, 2020	BUY	$32.38 - $44.96 $471,031 - $654,033	14,547 New	14,547 $424,000

164

106M

97.5K

45.6K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $305M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Souders Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Souders Financial Advisors with notifications on news.